PIVKA-II Antibody Assay for Diverse Under-Carboxylated Forms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing PIVKA-II assays fail to detect diverse subsets of under-carboxylated forms, limiting their clinical relevance and specificity in hepatocellular carcinoma diagnosis.
Innovation Solution
Development of novel monoclonal antibodies that preferentially bind to specific epitopes on PIVKA-II, independent of glutamic acid carboxylation at position 25, allowing for improved detection through a sandwich immunoassay.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing PIVKA-II assays using monoclonal antibody MU-3 are applied, then the assay can detect PIVKA-II, but it fails to detect diverse subsets of under-carboxylated forms, limiting clinical relevance and specificity
Solution Approach 1:
The patent develops a panel of monoclonal antibodies (including MU-3 and additional antibodies such as 3C10, 7A10, 4E8, 9A6, 13H7) that collectively detect multiple subsets of under-carboxylated PIVKA-II forms. Each antibody targets different epitopes, enabling the assay system to universally detect diverse carboxylation patterns rather than being limited to a single form.
Solution Approach 2:
The patent identifies and targets specific local epitopes within the PIVKA-II molecule, particularly focusing on the GLA domain and regions containing glutamic acid residues at positions 19, 20, and 25. By creating antibodies with different binding specificities to these local regions, the assay can distinguish between various under-carboxylated forms based on their unique epitope patterns.
2Reliability
If monoclonal antibody MU-3 is used which binds to epitope between amino acids 17-27 requiring Glu 19, Glu 20, and Glu 25, then the assay has defined binding specificity, but it cannot detect PIVKA-II forms with different carboxylation patterns at these positions
Solution Approach 1:
The patent systematically varies the binding parameters of different monoclonal antibodies by targeting different amino acid positions and carboxylation states. Instead of relying on a single antibody with fixed specificity requirements (Glu 19, Glu 20, Glu 25), the invention employs multiple antibodies with different epitope specificities, allowing the assay to adapt to various carboxylation patterns present in different PIVKA-II forms.
3Measurement precision
If a sandwich immunoassay is developed using novel monoclonal antibodies, then clinical sensitivity and specificity are improved, but the assay complexity increases
Solution Approach 1:
The patent divides the detection task into multiple segments by using a panel of monoclonal antibodies, each targeting specific epitopes. The sandwich immunoassay structure segments the detection process into capture and detection phases using different antibody pairs, allowing simultaneous measurement of multiple PIVKA-II subsets through a coordinated multi-component system rather than a single antibody approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel antibodies provide clinically meaningful data with enhanced specificity and sensitivity, particularly at high clinical sensitivity cutoffs, improving HCC diagnosis.
Implementation Method 1
novel monoclonal antibodies that preferentially bind to specific epitopes on PIVKA-II
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure relates to specific binding agents binding to different PIVKA-II forms as compared to antibodies known so far in the art.